RecruitingNCT07645391

Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

Sponsor

University of Michigan Rogel Cancer Center

Enrollment

200 participants

Start Date

Jan 1, 2017

Study Type

OBSERVATIONAL

Conditions

Prostate Carcinoma

Summary

This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.

Eligibility

Sex: MALEMin Age: 35 YearsMax Age: 70 Years

Inclusion Criteria9

* Age 35-70 years
Capable of providing informed consent
Prognosis of > 5 years if affected by another cancer
Patients need one to meet at least one of the following high genetic risk categories:
Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53
Carrier of mutation in a suspected PCa-related gene: e.g., ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1, FAM175A, HOXB13
Obligate carriers of the above mutations (e.g. their sisters/daughters have known mutations)
Men with any family history of above mutation
Family history of breast, prostate, or ovarian cancer in at least 2 individuals, or in 1 individual diagnosed before age 50